90 students experience bioprinting at Fluicell
We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…
Capital Markets Day, May 22
We invite you to participate in our Capital Markets Day for a look into Fluicell’s development and future…
05
May
2023
Bioprinted liver model application note
The liver plays a central role during drug development because of its function in drug metabolization. Having an…
26
Apr
2023
Årsstämma 2023
Aktieägarna i Fluicell AB (publ), org. nr 556889-3282, (”Bolaget”) kallas härmed till årsstämma onsdagen den 17 maj 2023…
17
Apr
2023
Fluicell CEO Newsletter 01, 2023
We at Fluicell have had an exciting start to this year, with advances across all three business areas….
11
Apr
2023
Dynaflow Resolve used in reserach showing potential new ways to treat pain
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
31
Mar
2023
A new era for Dynaflow Resolve
We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…
23
Mar
2023
Fluicell makes in vitro development progress in type 1 diabetes therapeutics program
Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…
16
Mar
2023
Fluicell at TERMIS-EU in Manchester
We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…
14
Mar
2023